Abbott 10-Q: Q3 GAAP EPS $0.53 as Exact Sciences Amortization and $1.05B Legal Charges Hit Earnings
ABT sits 41% above its 52-week low of $81.97.
Summary
Abbott's Q3 10-Q confirms $13.0B of sales (+14.5%) but GAAP EPS of just $0.53, weighed down by $841M of intangible amortization from Exact Sciences and $1.05B of infant-formula legal settlements. The filing also details the planned tax-free spinoff of the Nutrition business, targeted to close by the end of 2027.
Key Events · Earnings and Guidance · ABT
-
Q3 Sales Up 14.5%, GAAP EPS Halved
Net sales were $13,013M versus $11,369M a year ago, but net earnings fell to $920M and diluted EPS to $0.53 from $0.94, as amortization of intangibles rose to $841M from $420M.
-
Legal Charges Total $1.05B
The quarter carried a $670M charge to resolve the Gill case and NEC claims for about 2,000 additional infants, plus a $385M payment settling the DOJ qui tam matter.
-
Exact Sciences Deal Reshapes Balance Sheet
The $20.6B acquisition was funded with $20.0B of new long-term debt; long-term debt rose to $29,451M from $9,896M and cash fell to $4,052M from $8,522M, pushing quarterly net interest expense to $297M from $44M.
-
Purchase Accounting Adjusted Upward
A $3.2B increase in acquired intangible assets with a matching goodwill reduction added roughly $100M of amortization in the quarter; the allocation remains preliminary and could change materially.
Analysis · ABT · Life Sciences
The headline numbers were pre-released on October 21, but the full 10-Q shows how much of the profit decline is accounting rather than operating. Sales rose 14.5% to $13.0B, yet GAAP net earnings fell to $920M ($0.53 per diluted share) from $1,644M, because amortization of intangibles jumped to $841M from $420M after the Exact Sciences deal and SG&A absorbed $1.05B of legal settlements ($670M NEC/Gill, $385M DOJ). Operating earnings still grew at the segment level to $3,420M from $2,980M, so the shortfall sits below the operating line. The balance sheet is the other story: cash fell to $4.1B from $8.5B and long-term debt rose to $29.5B from $9.9B to fund the $20.6B acquisition, lifting net interest expense to $297M from $44M. Abbott also put mechanics on the Nutrition separation — a tax-free share distribution to holders targeted for completion by the end of 2027.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABT was trading at $115.48 on NYSE in the Life Sciences sector, with a market capitalization of approximately $199.9B. The 52-week trading range was $81.97 to $132.03. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.